Alexion Pharmaceuticals, Inc. (ALXN) Position Increased by Retirement Systems of Alabama

Retirement Systems of Alabama boosted its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 1.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 104,056 shares of the biopharmaceutical company’s stock after purchasing an additional 1,282 shares during the period. Retirement Systems of Alabama’s holdings in Alexion Pharmaceuticals were worth $14,066,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Captrust Financial Advisors acquired a new position in shares of Alexion Pharmaceuticals during the 4th quarter valued at $31,000. NuWave Investment Management LLC lifted its holdings in shares of Alexion Pharmaceuticals by 851.9% during the 4th quarter. NuWave Investment Management LLC now owns 514 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 460 shares in the last quarter. Kaizen Advisory LLC lifted its holdings in shares of Alexion Pharmaceuticals by 22.2% during the 4th quarter. Kaizen Advisory LLC now owns 610 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 111 shares in the last quarter. Benjamin F. Edwards & Company Inc. acquired a new position in shares of Alexion Pharmaceuticals during the 4th quarter valued at $68,000. Finally, We Are One Seven LLC acquired a new position in shares of Alexion Pharmaceuticals during the 4th quarter valued at $79,000. Hedge funds and other institutional investors own 94.79% of the company’s stock.

Several equities analysts recently weighed in on ALXN shares. Credit Suisse Group restated a “buy” rating and set a $156.00 target price on shares of Alexion Pharmaceuticals in a report on Tuesday, January 22nd. BidaskClub raised shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, January 22nd. Morgan Stanley lifted their price target on shares of Alexion Pharmaceuticals from $165.00 to $175.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 12th. Zacks Investment Research downgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, February 12th. Finally, Guggenheim began coverage on shares of Alexion Pharmaceuticals in a research note on Friday, February 22nd. They set a “neutral” rating and a $135.00 price target on the stock. Six research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $162.25.

In other Alexion Pharmaceuticals news, CAO Daniel Bazarko sold 2,000 shares of the business’s stock in a transaction dated Thursday, February 14th. The shares were sold at an average price of $126.00, for a total transaction of $252,000.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,020 shares of the company’s stock, valued at approximately $632,520. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.08% of the company’s stock.

Shares of NASDAQ:ALXN traded down $0.08 during trading on Friday, reaching $131.69. 1,323,731 shares of the company’s stock traded hands, compared to its average volume of 1,249,117. The company has a quick ratio of 3.36, a current ratio of 3.87 and a debt-to-equity ratio of 0.25. The company has a market cap of $29.53 billion, a PE ratio of 18.57, a P/E/G ratio of 1.04 and a beta of 1.53. Alexion Pharmaceuticals, Inc. has a 12 month low of $92.56 and a 12 month high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.40. The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.13 billion. Alexion Pharmaceuticals had a net margin of 9.59% and a return on equity of 19.53%. Alexion Pharmaceuticals’s revenue was up 22.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.68 EPS. As a group, research analysts forecast that Alexion Pharmaceuticals, Inc. will post 8.6 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/05/11/alexion-pharmaceuticals-inc-alxn-position-lifted-by-retirement-systems-of-alabama.html.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Story: What is the price-sales ratio?

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.